Results 11 to 20 of about 11,449,307 (399)
Awakening dormant glycosyltransferases in CHO cells with CRISPRa [PDF]
Biotechnology and Bioengineering, 2019 AbstractChinese hamster ovary (CHO) cells are the preferred workhorse for the biopharmaceutical industry, and CRISPR/Cas9 has proven powerful for generating targeted gene perturbations in CHO cells. Here, we expand the CRISPR engineering toolbox with CRISPR activation (CRISPRa) to increase transcription of endogenous genes.
Lasse Ebdrup Pedersen +12 more
openaire +7 more sources
Glycoengineering in CHO Cells: Advances in Systems Biology [PDF]
Biotechnology Journal, 2018 For several decades, glycoprotein biologics have been successfully produced from Chinese hamster ovary (CHO) cells. The therapeutic efficacy and potency of glycoprotein biologics are often dictated by their post‐translational modifications, particularly glycosylation, which unlike protein synthesis, is a non‐templated process. Consequently, both native
Vijay Tejwani +3 more
openaire +5 more sources
Production of α2,6-sialylated IgG1 in CHO cells [PDF]
mAbs, 2015 The presence of α2,6-sialic acids on the Fc N-glycan provides anti-inflammatory properties to the IgGs through a mechanism that remains unclear. Fc-sialylated IgGs are rare in humans as well as in industrial host cell lines such as Chinese hamster ovary (CHO) cells.
Raymond, Céline +5 more
openaire +4 more sources
The GalNAc-type O-Glycoproteome of CHO Cells Characterized by the SimpleCell Strategy [PDF]
Molecular & Cellular Proteomics, 2014 The Chinese hamster ovary cell (CHO) is the major host cell factory for recombinant production of biological therapeutics primarily because of its “human-like” glycosylation features.
Alder Schulz, Morten +12 more
core +2 more sources
Progress in fed-batch culture for recombinant protein production in CHO cells. [PDF]
Appl Microbiol Biotechnol, 2023 Nearly 80% of the approved human therapeutic antibodies are produced by Chinese Hamster Ovary (CHO) cells. To achieve better cell growth and high-yield recombinant protein, fed-batch culture is typically used for recombinant protein production in CHO ...
Xu WJ, Lin Y, Mi CL, Pang JY, Wang TY.
europepmc +2 more sources
Metabolic Profiling of CHO Cells during the Production of Biotherapeutics. [PDF]
Cells, 2022 As indicated by an ever-increasing number of FDA approvals, biotherapeutics constitute powerful tools for the treatment of various diseases, with monoclonal antibodies (mAbs) accounting for more than 50% of newly approved drugs between 2014 and 2018 ...
Coulet M +3 more
europepmc +2 more sources
Biotechnology Journal, 2021 Chinese Hamster Ovary [CHO] cells are the workhorse for production of modern biopharmaceuticals. They are however immortalized cells with a high propensity for genetic change.
Maria J. Wurm, F. Wurm
semanticscholar +1 more source
Production of trimeric SARS‐CoV‐2 spike protein by CHO cells for serological COVID‐19 testing
medRxiv, 2020 We describe scalable and cost‐efficient production of full length, His‐tagged severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) spike glycoprotein trimer by Chinese hamster ovary (CHO) cells that can be used to detect SARS‐CoV‐2 antibodies in ...
Yusuf B. Johari +15 more
semanticscholar +1 more source
Multi-copy targeted integration for accelerated development of high-producing CHO cells.
ACS Synthetic Biology, 2020 The ever-growing biopharmaceutical industry relies on the production of recombinant therapeutic proteins in Chinese hamster ovary (CHO) cells. The traditional timelines of CHO cell line development can be significantly shortened by the use of targeted ...
Daria Sergeeva +3 more
semanticscholar +1 more source
Caspase-7 deficiency in Chinese hamster ovary cells reduces cell proliferation and viability
Biological Research, 2020 Background Chinese hamster ovary (CHO) cells are the most commonly used mammalian host cell in the commercial-scale production of biopharmaceutical proteins. Modification of genes involved in apoptosis may improve the productivity of CHO cells. Executive
Fatemeh Safari +5 more
doaj +1 more source